PaxMedica(PXMD) - 2023 Q2 - Quarterly Report

Financial Performance - As of June 30, 2023, the accumulated deficit of Paxmedica, Inc. was approximately $41.1 million[123]. - For the three months ended June 30, 2023, total operating expenses were approximately $3.36 million, compared to $0.93 million for the same period in 2022, representing a 262% increase[135]. - General and administrative expenses for the three months ended June 30, 2023, were approximately $2.77 million, compared to $0.78 million in the same period in 2022, reflecting a 255% increase[136]. - Total operating expenses for the six months ended June 30, 2023, were approximately $7.4 million, compared to $2.9 million for the same period in 2022, reflecting a significant increase of 152%[142]. - Net loss for the six months ended June 30, 2023, was approximately $(7.3) million, compared to a net income of $1.9 million for the same period in 2022[142]. - Other income (expense) for Q2 2023 was approximately $(0.1) million, a decrease from $0.9 million in Q2 2022, primarily due to changes in fair value of notes and investments[141]. Research and Development - Research and development expenses for the three months ended June 30, 2023, were approximately $0.59 million, up from $0.15 million in the same period in 2022, indicating a 293% increase[137]. - The company expects to incur approximately $10.3 million in aggregate costs for research and development activities related to the filing of an NDA for HAT and an IND for ASD[140]. - Research and development expenses decreased to approximately $0.8 million for the six months ended June 30, 2023, from $1.2 million in 2022, a reduction of 33%[144]. - Research and development expenses primarily consist of salaries, benefits, and costs associated with clinical studies, with significant reliance on third-party contractors for clinical trials[178]. Funding and Capital Structure - During the six months ended June 30, 2023, the company received net proceeds of approximately $4.6 million from the issuance of 2.6 million shares of common stock[127]. - The company issued a convertible promissory note (the "2023 Note") with a principal balance of $3.7 million, receiving proceeds of approximately $2.5 million net of expenses[128]. - The estimated aggregate costs for filing an NDA for HAT and an IND for ASD are approximately $10.3 million, expected to be funded through IPO proceeds and future capital raising[147]. - The company received net proceeds of approximately $4.6 million from the issuance of 2.6 million shares of common stock under an equity purchase agreement with Lincoln Park Capital[150]. - As of June 30, 2023, the company had a cash balance of approximately $3.1 million, indicating a need for substantial additional funding to support ongoing operations[159]. Internal Controls and Compliance - The company has identified material weaknesses in internal control over financial reporting related to complex financial instruments, which have not been remediated as of June 30, 2023[184]. - A remediation plan has been developed to address the identified material weaknesses, with significant resources dedicated to improving internal control over financial reporting[186]. - The company has not experienced any changes in internal control over financial reporting that materially affected its controls during the fiscal quarter ended June 30, 2023[187]. - The company’s management has concluded that its controls around the interpretation and accounting for certain complex financial instruments were not effectively designed or maintained[183]. Business Operations - The company has not generated any product revenue to date, and its ability to do so depends on the successful development and commercialization of its product candidates[131]. - The company anticipates significant increases in expenses related to its ongoing development activities and operating as a public company[134]. - The company has not paid dividends on its common stock and does not expect to do so in the foreseeable future, using an expected dividend yield of zero[173]. - The company is classified as an emerging growth company and intends to rely on certain exemptions from public company reporting requirements for up to five years following its initial public offering[180]. Agreements and Contracts - An exclusive distribution agreement with Vox Nova, LLC includes an upfront exclusivity fee of $0.5 million and a total potential fee of up to $2.0 million based on regulatory approval[130]. - An exclusive distribution agreement with Vox Nova for PAX-101 includes an upfront fee of $0.5 million and potential additional payments totaling up to $2.0 million upon FDA approval[153]. Fair Value and Accounting - The company has elected the fair value option for recognition of its convertible notes, recognizing them at fair value with changes in fair value reflected in the statements of operations[176]. - The fair value of common stock will now be determined based on the closing price on the date of grant, following the establishment of a public trading market[174]. - The company has accrued expenses for preclinical studies and clinical trials based on estimated percentage of work completed and contract milestones remaining[177].